HeartBeam announced the issuance of two new U.S. patents that strengthen its intellectual property portfolio and support the company's expansion in remote cardiac diagnostics. The new patents protect core technologies behind HeartBeam's compact, cable-free 3D ECG device and its rhythm analysis algorithm capable of identifying arrhythmias through continuous signal input.
The 3D ECG device, which uses chest and finger electrodes to collect high-fidelity signals in three non-coplanar directions, is designed for on-demand symptom recording and 12-lead ECG synthesis. Its software is currently under FDA review, backed by data from the VALID-ECG pivotal study. The rhythm algorithm works across cardiac monitoring systems and triggers targeted data collection during abnormal rhythm detection, enhancing diagnostic precision.
With 20 issued patents and 34 additional filings, HeartBeam continues to solidify its position at the forefront of digital cardiac care innovation, with future plans to incorporate AI capabilities for enhanced diagnostic accuracy. This development is significant as it addresses the growing need for remote cardiac monitoring solutions that can provide accurate diagnostics outside traditional medical facilities, potentially improving patient outcomes through early detection and intervention.
The company's technology platform represents a shift toward decentralized cardiac care, enabling physicians to identify cardiac health trends and acute conditions while patients remain in their preferred environments. For more information about the company's technology, visit https://www.HeartBeam.com. The latest updates relating to the company are available at https://ibn.fm/BEAT.
